Role of the incretin system in the remission of type 2 diabetes following bariatric surgery.
OBJECTIVE
It has been observed, as a collateral outcome of bariatric surgery, that morbidly obese patients with frank type 2 diabetes mellitus or impaired glucose tolerance undergone Roux-en-Y Gastric Bypass (RYGB) or bilio-pancreatic diversion (BPD) became and remained euglycemic since surgery. But, most interestingly, the conversion to euglycemia happened within few days from the operation, long before a significant weight loss could intervene. The purpose of this viewpoint is to try to elucidate the mechanisms involved in the resolution/remission of diabetes after bariatric surgery, in particular highlighting the role played by the modifications in incretin secretion.


RESULTS
The effect of purely restrictive procedures in improving glucose control is directly proportional to the degree of weight loss. In contrast, either RYGB or BPD, the first a mainly restrictive and the second a quite purely malabsorptive bariatric technique, operate through a different mechanism, as a probable consequence of the small intestine bypass. The bypass of different intestinal portions covers a central role in the mechanisms of action of these two surgical procedures. In fact, while RYGB does not affect insulin resistance but increases insulin secretion via the stimulation of nutrient-mediated incretin secretion, BPD induces a full normalization of insulin resistance and, consequently, a significant reduction of insulin secretion. The insulin resistance reversion is only partially explained by the incretin level changes after BPD.


CONCLUSIONS
A role of incretins in type 2 diabetes improvement or resolution is ascertained although it is possible that other, not yet identified, hormone(s) can cooperate with them.
Mingrone
G
G
Department of Internal Medicine, Università Cattolica Sacro Cuore, Largo Agostino Gemelli, 8, Rome, Italy. gmingrone@rm.unicatt.it
D050110:Bariatric Surgery; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000601:surgery*; D015390:Gastric Bypass / Q000379:methods*; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000601:surgery; D006801:Humans; D054795:Incretins / Q000502:physiology*; D007333:Insulin Resistance / Q000502:physiology; D009767:Obesity, Morbid / Q000150:complications* / Q000601:surgery*; D052336:Proglucagon / Q000378:metabolism; D012074:Remission Induction; D015431:Weight Loss
D001786:Blood Glucose; D054795:Incretins; D052336:Proglucagon